Wednesday, July 8, 2026

pharma · Non-Alcoholic Fatty Liver Disease · Non-alcoholic Steatohepatitis (NASH) Cirrhosis · MDGL

Madrigal Pharmaceuticals EU

News and analysis for Madrigal Pharmaceuticals EU on NovaPharmaNews — regulatory, clinical, and market coverage.

200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US HQ
2016 Founded
1,071 Employees
Public company Type
MDGL · NYSE Ticker
Company details
Status
Public
HQ
200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US
Founded
2016
Employees
1,071
Programs
16
Drugs
11
Patents
26
Intelligence · Coverage

News & analysis

NovaPharmaNews articles mentioning Madrigal Pharmaceuticals EU — regulatory, clinical, and market coverage.

News and analysis for Madrigal Pharmaceuticals EU on NovaPharmaNews — regulatory, clinical, and market coverage.

No coverage yet

We have not published news or analysis mentioning Madrigal Pharmaceuticals EU yet.

Back to company overview →